Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme 1 Polymorphisms and Prognosis among Women Treated with Breast Cancer

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.
Kristin E. Anderson, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota
Minneapolis, MN 55455-2070

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
REPORT DOCUMENTATION PAGE

1. AGENCY USE ONLY (Leave blank)
2. REPORT DATE
October 2004
3. REPORT TYPE AND DATES COVERED
Annual (28 Sep 2003 - 27 Sep 2004)

4. TITLE AND SUBTITLE
Metabolizing Enzyme 1 Polymorphisms and Prognosis among Women Treated with Breast Cancer

5. FUNDING NUMBERS
DAMD17-01-1-0128

6. AUTHOR(S)
Carol Sweeney, Ph.D.
Kristin E. Anderson, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Minnesota
Minneapolis, MN 55455-2070

8. PERFORMING ORGANIZATION REPORT NUMBER

E-Mail: csweeney@hrc.utah.edu

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)
This study uses archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. During year 3, we have completed review of over 750 potentially eligible cases and have collected tissue blocks for over 400, so that collection of tissue samples (SOW Task 2) is almost complete. We have obtained updated vital status and cause of death information for eligible subjects. An extension of the project into a fourth year has been approved. Laboratory assays to detect genotypes and tumor markers will be conducted during year 4. No reportable scientific results are available at the end of year 3.

14. SUBJECT TERMS
Breast Cancer

15. NUMBER OF PAGES
8

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
Unclassified

20. LIMITATION OF ABSTRACT
Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102
Table of Contents

Cover.................................................................1
SF 298..............................................................2
Introduction.......................................................4
Body.................................................................5
Key Research Accomplishments..............................7
Reportable Outcomes...........................................7
Conclusions.......................................................7
References.........................................................8
Appendices.......................................................N/A
INTRODUCTION

This study uses archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. We had reported from a pilot study that carrying the homozygous genotype for the glutathione S-transferase (GST)P1 Val^105 variant, associated with lower enzymes activity toward alkylating agents, or the homozygous genotype for GSTA1*B, a promoter variant that reduces hepatic expression of GSTA1, predicted improved overall among women treated for breast cancer (1, 2). The present, DOD-funded study, extends this area of research to a larger population of women treated for breast cancer and will consider whether these associations are independent of other prognostic markers in tumor tissue. The study design is a retrospective cohort; subject who received first course of therapy for invasive, primary breast cancer at an academic medical center have been identified through the hospital tumor registry. Archived pathological tissue blocks for these women will be the source of tissue for laboratory assays. Genotypes will be determined from normal DNA, and prognostic markers will be evaluated by immunohistochemistry. We will evaluate associations between genotypes and recurrence and overall survival, taking into account other prognostic markers.
The Statement of Work identified five tasks, as follows:

Task 1. Compilation of Data for Eligible Subjects
Task 2. Archived Tissue Specimens Obtained
Task 3. DNA Extraction and Genotyping
Task 4. Immunohistochemistry
Task 5. Data Analysis and Report Writing

Task 1 was completed during the first year of funding.

Task 2 was initiated during year 2.

During year 3, we have proceeded with Task 2, collecting tissue samples. A total of 771 potentially eligible cases from 3 hospitals were identified by the Fairview University Medical Centers (FUMC) tumor registry have been reviewed by the study coordinator. Of these cases, over 200 could not be included because pathology records and/or tissue could not be obtained (Table 1).

Table 1. Summary of potentially eligible breast cancer cases reviewed

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ineligible</td>
<td></td>
</tr>
<tr>
<td>No pathology reports exists in FUMC system</td>
<td>80</td>
</tr>
<tr>
<td>In situ disease only</td>
<td>5</td>
</tr>
<tr>
<td>No tissue available</td>
<td></td>
</tr>
<tr>
<td>No tissue blocks available</td>
<td>136</td>
</tr>
<tr>
<td>Core biopsy tissue only</td>
<td>32</td>
</tr>
<tr>
<td>In process</td>
<td></td>
</tr>
<tr>
<td>Requesting slides/blocks</td>
<td>35</td>
</tr>
<tr>
<td>Need further review of pathology</td>
<td>23</td>
</tr>
<tr>
<td>Completed</td>
<td></td>
</tr>
<tr>
<td>Review complete, blocks obtained</td>
<td>460</td>
</tr>
</tbody>
</table>
For the remaining cases, except for those in process (requesting pathological material) or requiring further review, the study pathologist has reviewed slides and, if the case was eligible on pathological criteria, has selected a normal lymph node block for DNA extraction and a block containing representative tumor tissue for immunohistochemical staining. Tissue sections are have been cut and mounted on slides for over 400 of the cases obtained to date so that material is ready and laboratory assays for Tasks 3 and 4 will start soon.

During year 3 we have obtained updated vital status and cause of death information for eligible subjects through linkage with electronic Minnesota death certificate records.

Unexpected obstacles have been encountered during data collection, resulting in slower progress than what was outlined the original statement of work. A primary problem has been that the proportion of potentially eligible cases with no pathology record in the FUMC system, or no tissue blocks available, is larger than anticipated. Therefore it was not possible to collect samples for an adequate number of study subjects from one hospital as had been originally planned. We expanded the study to several hospitals within the FUMC system in order to accrue a sufficient number of samples. Working with additional hospitals, however, created the necessity of submitting, and waiting for approval of, revisions to IRB the protocols. To work with more hospitals we also needed to hire and train additional part-time personnel. This additional administrative workload on the PI and study coordinator contributed to slower-than-anticipated progress during year 2 and the early part of year 3. Substantial progress has been made during the balance of year 3, and an extension of the project period into year 4 has been approved. At present, in October, 2004, progress on the research has been
slowed while we wait for a response from the DOD IRB to a protocol revision submitted in April, 2004, which included addition of one more FUMC hospital as a source of tissue for the study. If approval of this revision is not received soon, the project will fall further behind schedule and we will not be able to increase the sample size to what was originally planned.

KEY RESEARCH ACCOMPLISHMENTS

Tasks 3, 4, and 5 are yet to be completed. Laboratory assays for genotypes and pathological markers will be underway shortly. No reportable scientific results will be available until these tasks are complete. The PI presented a poster describing study methods and rationale at the “Era of Hope” Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

REPORTABLE OUTCOMES

Abstract


CONCLUSIONS

Data collection tasks are ongoing, so no reportable scientific results are available to date.
REFERENCES


APPENDICES

N/A